Patents by Inventor Hardy Kornfeld
Hardy Kornfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120213790Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 20, 2012Publication date: August 23, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20110207679Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: February 18, 2011Publication date: August 25, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7914778Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: March 16, 2007Date of Patent: March 29, 2011Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20100008936Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 16, 2007Publication date: January 14, 2010Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7608691Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: October 6, 2006Date of Patent: October 27, 2009Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7232801Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: June 27, 2005Date of Patent: June 19, 2007Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 7208149Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: GrantFiled: February 5, 2003Date of Patent: April 24, 2007Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20070031375Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: October 6, 2006Publication date: February 8, 2007Applicant: Trustees of Boston UniversityInventors: David Center, William Cruikshank, Hardy Kornfeld
-
Patent number: 7019118Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: August 15, 2001Date of Patent: March 28, 2006Assignee: Trustees of Boston UniversityInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20050267039Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: ApplicationFiled: June 27, 2005Publication date: December 1, 2005Inventors: David Center, William Cruikshank, Hardy Kornfeld
-
Patent number: 6723697Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.Type: GrantFiled: August 15, 2001Date of Patent: April 20, 2004Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 6699466Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16-mediated disorders such as certain inflammatory diseases.Type: GrantFiled: August 5, 1999Date of Patent: March 2, 2004Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20030153504Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: February 5, 2003Publication date: August 14, 2003Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20030017990Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans.Type: ApplicationFiled: August 15, 2001Publication date: January 23, 2003Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20020147151Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans.Type: ApplicationFiled: August 15, 2001Publication date: October 10, 2002Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 6159463Abstract: Purified DNA encoding LCF and the recombinant proteins expressed from such DNA are disclosed. In addition, the invention provides methods for suppressing an LCF-CD4 interaction and screening candidate LCF agonists or antagonists. The invention also provides compositions and methods useful for stimulating proliferation of CD4+ T-cells in a mammal.Type: GrantFiled: December 29, 1995Date of Patent: December 12, 2000Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 5976522Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.Type: GrantFiled: December 29, 1995Date of Patent: November 2, 1999Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 5965120Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.Type: GrantFiled: December 29, 1995Date of Patent: October 12, 1999Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 5869263Abstract: Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.Type: GrantFiled: December 29, 1995Date of Patent: February 9, 1999Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Patent number: 5807712Abstract: Purified DNA encoding lyphocyte chemoattractant factor (LCF) and the recombinant proteins expressed from such DNA are disclosed. In addition, the invention provides methods for suppressing an LCF-CD4 interaction and screening candidate LCF agonists or antagonists. The invention also provides compositions and methods useful for stimulating proliferation of CD4+ T-cells in a mammal.Type: GrantFiled: December 13, 1994Date of Patent: September 15, 1998Assignee: Research Corporation Technologies, Inc.Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld